Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
22 oct. 2024 16h01 HE
|
Tectonic Therapeutic
WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of...
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
19 sept. 2024 16h01 HE
|
Tectonic Therapeutic
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at...
Tectonic Therapeutic to Participate in September Investor Conferences
20 août 2024 16h01 HE
|
Tectonic Therapeutic
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
14 août 2024 16h01 HE
|
Tectonic Therapeutic
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
30 juil. 2024 16h01 HE
|
Tectonic Therapeutic
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
01 févr. 2019 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and...
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
18 janv. 2019 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy...
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
17 janv. 2019 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related...
AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
07 janv. 2019 07h06 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D.,...
AVROBIO, Inc. Added to NASDAQ Biotechnology Index
21 déc. 2018 10h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected...